POST 18th_ELSF
​> ATTENDEES​
​​> INVESTORS​
> PRESENTERS​
​> SPONSORS​
​> SUPPORTERS​

silver sponsor

Stifel

Stifel is a full-service investment bank with deep industry experience. We serve as strategic advisors to entrepreneurs, family-owned businesses, private equity groups, and leading public and private corporations in North America, Europe, Asia, and Latin America.

Our full-service healthcare investment banking practice offers a best-in-class combination of deep sector knowledge, strong industry relationships, and broad product expertise.

We are not bound by borders. We stand ready to provide the insight and expertise you require. Our integrated approach allows us to deliver the full capabilities of Stifel’s institutional capital markets platform and retail brokerage network, which are among the most highly regarded in the industry.

https://stifelinstitutional.com/capabilities/investment-banking/industry-coverage/healthcare/

bronze sponsor

Eli Lilly and Company

At Lilly, we take smart risks on bold science to achieve our mission of bringing life-changing medicines to patients. As a community of scientists, we understand the brilliance and dedication this work takes. We also recognize our responsibility as partners to help advance life-changing medicines within our walls and beyond. More than 100 years ago, we pioneered strategic collaborations to scale the bold work of four University of Toronto research scientists to launch the world’s first commercial insulin. We're proud to continue our legacy in collaboration, with ~50% of our new product launches in the last 10 years enabled by external innovation, and over 70 active alliances with the vibrant academic and biotech ecosystem. We know that every partnership is different - from stage, modality, therapeutic area, and culture. We have the skill, capabilities, and know-how to bring a holistic suite of models to life to continuously meet your needs. Let’s grow together!

www.lilly.com/partners/scientific-partnering-areas-of-interest

Invest Hong Kong

Invest Hong Kong is the Investment Agency for the Hong Kong Government. We are able to offer you a multitude of grants and tax incentives when doing R&D or Clinical Trials in Hong Kong as well as in-depth market research and unique business opportunities. We became the leading Biotech IPO Destination in Asia and related we would like to discuss with you how to proliferate your company within our hub. We are seeking promising biomedical companies inspired to conduct R&D works in Hong Kong within Infectious Diseases, CNS, Immune Disorders, Cardiovascular, Oncology, Digital Health and Medical AI.

www.investhk.gov.hk/en/home.html

contributing sponsorS

​Cancer Research Horizons

Cancer Research Horizons is the innovation engine of Cancer Research UK – the world's largest charitable funder of cancer research.

With access to Cancer Research UK’s network of 4,000 exceptional scientists and funding of £400m of world-class academic research each year, Cancer Research Horizons is chaning the way we prevent, diagnose and treat cancer. The Company offers the full spectrum of translational expertise, from drug discovery and clinical capabilities, translational funding and entrepreneurial training to licensing, industry collaboration and start- up creation expertise. It has played a role in the creation of 79 start-ups, with its portfolio companies raising over £3bn in total capital.

Its dedicated Ventures team focuses on early-stage, high-risk companies, including one of the most challenging stages or start-up creation: attracting early-stage risk capital. The Ventures team manages the Cancer Research Horizons Seed Fund, launched in June 2022, to accelerate more breakthroughs to patient benefit.

www.cancerresearchhorizons.com

Novo Holdings A/S

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.
 
Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk and Novonesis and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Principal Investments, Planetary Health Investments and Asia teams, Novo Holdings invests in life science companies at all stages of development.
 
As of year-end 2023, Novo Holdings had total assets of EUR 149 billion. 

www.novoholdings.dk